Clinical Trial Update: Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for Tandutinib in patients who had surgery for metastatic renal cell carcinoma, including clear cell and recurrent disease; results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Tandutinib (tandutinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-02-04